journal article·2017-12-06

CuS-Based Theranostic Micelles for NIR-Controlled Combination Chemotherapy and Photothermal Therapy and Photoacoustic Imaging

Guojun Chen, Ben Ma, Yuyuan Wang, Ruosen Xie, Chun Li, Kefeng Dou, Shaoqin Gong

Publisher page

Abstract

Cancer remains a major threat to human health due to low therapeutic efficacies of currently available cancer treatment options. Nanotheranostics, capable of simultaneous therapy and diagnosis/monitoring of diseases, has attracted increasing amounts of attention, particularly for cancer treatment. In this study, CuS-based theranostic micelles capable of simultaneous combination chemotherapy and photothermal therapy (PTT), as well as photoacoustic imaging, were developed for targeted cancer therapy. The micelle was formed by a CuS nanoparticle (NP) functionalized by thermosensitive amphiphilic poly(acrylamide-acrylonitrile)-poly(ethylene glycol) block copolymers. CuS NPs under near-infrared (NIR) irradiation induced a significant temperature elevation, thereby enabling NIR-triggered PTT. Moreover, the hydrophobic core formed by poly(acrylamide-acrylonitrile) segments used for drug encapsulation exhibited an upper critical solution temperature (UCST; ∼38 °C), which underwent a hydrophobic-to-hydrophilic transition once the temperature rose above the UCST induced by NIR-irradiated CuS NPs, thereby triggering a rapid drug release and enabling NIR-controlled chemotherapy. The CuS-based micelles conjugated with GE11 peptides were tested in an epidermal growth factor receptor-overexpressing triple-negative breast cancer model. In both two-dimensional monolayer cell and three-dimensional multicellular tumor spheroid models, GE11-tagged CuS-based micelles under NIR irradiation, enabling the combination chemotherapy and PTT, exhibited the best therapeutic outcome due to a synergistic effect. These CuS-based micelles also displayed a good photoacoustic imaging ability under NIR illumination. Taken together, this multifunctional CuS-based micelle could be a promising nanoplatform for targeted cancer nanotheranostics.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Photoacoustic and Ultrasonic Imaging · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical University, Xi’an, Shaanxi 710032, China

Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas 77054, United States

Funding

National Cancer Institute

References (56)

Show source-provided references
1. 10.1002/adma.20110231310.1002/adma.201102313 ↗
2. 10.1021/cr400532z10.1021/cr400532z ↗
3. 10.1038/nrc188610.1038/nrc1886 ↗
4. 10.1038/nrd198410.1038/nrd1984 ↗
5. 10.1158/1078-0432.CCR-07-144110.1158/1078-0432.CCR-07-1441 ↗
6. 10.1038/natrevmats.2017.2410.1038/natrevmats.2017.24 ↗
7. 10.7150/thno.1533510.7150/thno.15335 ↗
8. 10.1002/smll.20160063510.1002/smll.201600635 ↗
9. 10.1073/pnas.070746110410.1073/pnas.0707461104 ↗
10. 10.1016/j.biomaterials.2016.04.02910.1016/j.biomaterials.2016.04.029 ↗
11. 10.1016/j.addr.2012.10.00210.1016/j.addr.2012.10.002 ↗
12. 10.1016/j.biomaterials.2016.05.04110.1016/j.biomaterials.2016.05.041 ↗
13. 10.7150/thno.1521710.7150/thno.15217 ↗
14. 10.1016/j.jconrel.2007.12.01710.1016/j.jconrel.2007.12.017 ↗
15. 10.7150/thno.734110.7150/thno.7341 ↗
16. 10.1039/C4CS00014E10.1039/C4CS00014E ↗
17. 10.1016/j.biomaterials.2015.01.00610.1016/j.biomaterials.2015.01.006 ↗
18. 10.1021/acs.chemrev.5b0032110.1021/acs.chemrev.5b00321 ↗
19. 10.1016/j.biomaterials.2013.07.08510.1016/j.biomaterials.2013.07.085 ↗
20. 10.1166/jbn.2014.188610.1166/jbn.2014.1886 ↗
21. 10.1021/nn400334y10.1021/nn400334y ↗
22. 10.1021/nn401717910.1021/nn4017179 ↗
23. 10.1016/j.molmed.2015.01.00110.1016/j.molmed.2015.01.001 ↗
24. 10.7150/thno.1498810.7150/thno.14988 ↗
25. 10.1039/C4NR00708E10.1039/C4NR00708E ↗
26. 10.1021/acs.jpcc.5b1123210.1021/acs.jpcc.5b11232 ↗
27. 10.1021/nn507241v10.1021/nn507241v ↗
28. 10.1021/ja106855m10.1021/ja106855m ↗
29. 10.1021/nn302782y10.1021/nn302782y ↗
30. 10.1063/1.219502410.1063/1.2195024 ↗
31. 10.1021/ma300355k10.1021/ma300355k ↗
32. 10.1002/adfm.20160467110.1002/adfm.201604671 ↗
33. 10.1016/j.biomaterials.2013.01.08410.1016/j.biomaterials.2013.01.084 ↗
34. 10.1002/anie.20110380610.1002/anie.201103806 ↗
35. 10.1016/j.jconrel.2008.01.00710.1016/j.jconrel.2008.01.007 ↗
36. 10.1016/j.jconrel.2017.01.04210.1016/j.jconrel.2017.01.042 ↗
37. 10.1071/CH0906210.1071/CH09062 ↗
38. 10.1021/ma402370j10.1021/ma402370j ↗
39. 10.1016/j.ab.2013.02.00410.1016/j.ab.2013.02.004 ↗
40. 10.1089/ten.tec.2015.028010.1089/ten.tec.2015.0280 ↗
41. 10.1038/nnano.2011.16610.1038/nnano.2011.166 ↗
42. 10.1038/nrd261410.1038/nrd2614 ↗
43. 10.1002/adma.20110129510.1002/adma.201101295 ↗
44. 10.1016/j.biomaterials.2011.10.01710.1016/j.biomaterials.2011.10.017 ↗
45. 10.1021/nn900215k10.1021/nn900215k ↗
46. 10.1073/pnas.72.3.93710.1073/pnas.72.3.937 ↗
47. 10.1038/nrm223610.1038/nrm2236 ↗
48. 10.1021/mp300595a10.1021/mp300595a ↗
49. 10.1021/mp400751g10.1021/mp400751g ↗
50. 10.3892/ol.2014.244910.3892/ol.2014.2449 ↗
51. 10.1016/j.actbio.2013.11.00310.1016/j.actbio.2013.11.003 ↗
52. 10.1021/nn100736c10.1021/nn100736c ↗
53. 10.1038/nnano.2008.23110.1038/nnano.2008.231 ↗
54. 10.1021/acs.bioconjchem.6b0015610.1021/acs.bioconjchem.6b00156 ↗
55. 10.1021/acs.nanolett.7b0210510.1021/acs.nanolett.7b02105 ↗
56. 10.1021/nn302782y10.1021/nn302782y ↗